Barriers to Accessing New Anti-Diabetes Medications

Author(s):

Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.

EP: 1.Defining Resistant Diabetes

EP: 2.Differentiating Medication Non-Adherence From Underlying Comorbidities

Now Viewing

Barriers to Accessing New Anti-Diabetes Medications

EP: 1.Defining Resistant Diabetes

EP: 2.Differentiating Medication Non-Adherence From Underlying Comorbidities

EP: 3.Barriers to Accessing New Anti-Diabetes Medications

EP: 4.Suspecting Hypercortisolism in Patients With Resistant Diabetes

EP: 5.Testing for Hypercortisolism

EP: 6.Patient Subgroups With a Higher Prevalence of Hypercortisolism

EP: 7.Evolving Perception of Autonomous Adrenal Hypercortisolism

EP: 8.Pathophysiology of Hypercortisolism

EP: 9.Need to Address Underlying Hypercortisolism

EP: 10.Approaching Treatment in Hypercortisolism

EP: 11.Choosing Between Medical and Surgical Options for Hypercortisolism

EP: 12.Long-Term Outcomes for Patients Treated for Hypercortisolism